Pfizer was established in 1849 in Brooklyn, New York by cousins Charles Pfizer and Charles Erhart with a loan of $2,500 from Pfizer’s father.2 Today, 167 years later, Pfizer Inc. has international revenues of $49 billion, which makes it the second-largest pharmaceutical manufacturer in the world.3 Despite Pfizer’s success, the company has faced many challenges over the last few decades. The pharmaceutical industry is heavily influenced by legal, political, and technological forces, and all indications are that the industry will continue to experience dramatic changes
The study aims at describing leadership change in the pharmaceutical industry from the viewpoint of ...
This paper explored an unusually comprehensive dataset of more than 2,000 drug R&D projects all over...
In the research-intensive pharmaceutical industry, two rationales for M&A prevail. First, deals may ...
This case focus on the strategy that motivated Pfizer to go, by 2009, through the acquisition of Wy...
This paper addresses a few major problems that the pharmaceutical company Pfizer Inc. has recently b...
If there is one topic that has drastically affected human society in the last decades, it definitely...
This project develops an extensive valuation of Pfizer Inc. under the CFA institute’s “Equit...
The biotechnology and pharmaceutical industries are facing significant challenges to their existing ...
The traditional heavyweights or big pharmas of the modern pharmaceutical industry are facing unprece...
Is Pfizer-Wyeth merger aligned with value creation in the pharmaceutical industry? This empirical r...
The recent AstraZeneca takeover bid from Pfizer puts pharmaceutical R&D once again on the public age...
The healthcare costs in the United States are growing at an alarming rate. With the costs expected t...
As the price of medication skyrockets in 2017, investigating large pharmaceutical companies’ behavio...
On November 23, 2015, the US drugs giant Pfizer has entered into a definitive merger agreement under...
Atlanta Conference on Science and Innovation Policy 2009This presentation was part of the session : ...
The study aims at describing leadership change in the pharmaceutical industry from the viewpoint of ...
This paper explored an unusually comprehensive dataset of more than 2,000 drug R&D projects all over...
In the research-intensive pharmaceutical industry, two rationales for M&A prevail. First, deals may ...
This case focus on the strategy that motivated Pfizer to go, by 2009, through the acquisition of Wy...
This paper addresses a few major problems that the pharmaceutical company Pfizer Inc. has recently b...
If there is one topic that has drastically affected human society in the last decades, it definitely...
This project develops an extensive valuation of Pfizer Inc. under the CFA institute’s “Equit...
The biotechnology and pharmaceutical industries are facing significant challenges to their existing ...
The traditional heavyweights or big pharmas of the modern pharmaceutical industry are facing unprece...
Is Pfizer-Wyeth merger aligned with value creation in the pharmaceutical industry? This empirical r...
The recent AstraZeneca takeover bid from Pfizer puts pharmaceutical R&D once again on the public age...
The healthcare costs in the United States are growing at an alarming rate. With the costs expected t...
As the price of medication skyrockets in 2017, investigating large pharmaceutical companies’ behavio...
On November 23, 2015, the US drugs giant Pfizer has entered into a definitive merger agreement under...
Atlanta Conference on Science and Innovation Policy 2009This presentation was part of the session : ...
The study aims at describing leadership change in the pharmaceutical industry from the viewpoint of ...
This paper explored an unusually comprehensive dataset of more than 2,000 drug R&D projects all over...
In the research-intensive pharmaceutical industry, two rationales for M&A prevail. First, deals may ...